ClinicalTrials.gg

TargetBeta

CD8A

CD8 subunit alpha · also p32, CD8alpha, CD8 · CD molecules

6 programs in company-led studies act on CD8A, from 3 companies: 0 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
zamtocabtagene autoleucelruleMiltenyi Biomedicinephase 287 runningCD19, CD4, MS4A1NCIt
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 222 runningCD3E, MS4A1a judged reading
Anti-GPC3 T Cell-engaging Antibody AZD9793AstraZenecaphase 211 runningCD3E, GPC3a judged reading
Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621AstraZenecaphase 211 runningCD3E, STEAP2a judged reading
CD8-guided IL-2 Fusion Protein AZD6750AstraZenecaphase 211 runningIL2RB, IL2RGa judged reading
etakafusp alfaruleAmgenphase 122 running–NCIt

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.